Which selective serotonin reuptake inhibitor (SSRI) has the lowest potential for drug‑drug interactions?

Citalopram and Escitalopram Have the Lowest Drug-Drug Interaction Potential Among SSRIs

Citalopram and escitalopram are the SSRIs with the least effect on CYP450 isoenzymes and therefore have the lowest propensity for drug-drug interactions 1. This makes them the preferred choice when minimizing drug interactions is a clinical priority.

Ranking SSRIs by Drug Interaction Risk

Lowest Risk (Preferred)

• Citalopram/Escitalopram: Minimal CYP450 inhibition across all isoenzymes 1, 2, 3
• Sertraline: Weak CYP2D6 inhibitor at therapeutic doses; only becomes significant at high doses 2, 4

Moderate Risk

• Fluoxetine: Potent CYP2D6 inhibitor with mild CYP3A4 effects; interactions persist for weeks after discontinuation due to long half-life of active metabolite norfluoxetine 2, 4
• Paroxetine: Potent CYP2D6 inhibitor 2, 4

Highest Risk (Avoid When Possible)

• Fluvoxamine: Inhibits multiple pathways (CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6), creating the greatest potential for drug interactions 1, 2, 4

Clinical Implications by CYP Enzyme System

CYP2D6 interactions (affects ~30 commonly used drugs including tricyclics, antipsychotics, beta-blockers, opioids):

• Fluoxetine and paroxetine cause potent inhibition
• Sertraline causes mild inhibition at standard doses
• Citalopram/escitalopram have minimal effect 1, 2

CYP1A2 interactions (affects caffeine, clozapine, olanzapine, theophylline):

• Fluvoxamine is the only SSRI with potent inhibition 5

CYP3A4 interactions (most abundant liver enzyme, affects many medications):

• Most SSRIs have negligible effects except norfluoxetine (fluoxetine metabolite) 5

Additional Safety Considerations

While drug interactions are your primary concern, note that citalopram and escitalopram carry QT prolongation risk, particularly at doses >40 mg/day for citalopram 1, 6. The 2023 Canadian Cardiovascular Society guidelines specifically note that among SSRIs, risk of QT prolongation is highest with citalopram and escitalopram, and negligible with paroxetine and sertraline 6.

Practical Prescribing Algorithm

When drug interaction risk is the primary concern:

1. First choice: Citalopram or escitalopram (if no cardiac risk factors)
2. Second choice: Sertraline at standard doses (≤200 mg/day)
3. Avoid: Fluvoxamine in polypharmacy situations

When both drug interactions AND cardiac risk factors exist:

1. First choice: Sertraline (negligible QT risk, low interaction potential at standard doses)
2. Alternative: Paroxetine (negligible QT risk but moderate CYP2D6 inhibition)

Common Pitfalls to Avoid

• Don't assume all SSRIs are equivalent for drug interactions—the differences are clinically significant 2, 4
• Remember that fluoxetine's long half-life means interactions can persist for weeks after discontinuation 2
• Fluvoxamine's multi-enzyme inhibition makes it particularly problematic in elderly patients on multiple medications 1
• When adding any medication to an SSRI regimen, check for CYP-mediated interactions, particularly with drugs having narrow therapeutic indices (antiarrhythmics, anticoagulants, antiepileptics) 1